%0 Journal Article
%A DuBois, Steven G
%A Moreno, Lucas
%A Anderson, John
%A Asgharzadeh, Shahab
%A Bagatell, Ro
%A Beck-Popovic, Maja
%A Belle, Jen
%A Berlanga, Pablo
%A Bird, Nick J
%A Chesler, Louis
%A Durbin, Adam
%A Eggert, Angelika
%A Eilers, Martin
%A Federico, Sara M
%A Fischer, Matthias
%A Gatz, Susanne A
%A George, Rani E
%A George, Sally
%A Goldsmith, Kelly C
%A Gray, Juliet
%A Heczey, Andras
%A Irwin, Meredith S
%A Knox, Leona
%A Lode, Holger N
%A Ludwinski, Donna
%A Macy, Margaret E
%A Majzner, Robbie G
%A Maris, John M
%A Modak, Shakeel
%A Molenaar, Jan J
%A Morgenstern, Daniel A
%A Mossé, Yael P
%A Owens, Cormac
%A Reynolds, C Patrick
%A Rossig, Claudia
%A Schleiermacher, Gudrun
%A Scott, Liz
%A Sondel, Paul M
%A Speleman, Frank
%A van Noesel, Max
%A Westermann, Frank
%A Wienke, Judith
%A Wolpaw, Adam J
%A Park, Julie R
%A Pearson, Andrew D J
%T Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
%J Pediatric blood & cancer
%V 72
%N 9
%@ 1545-5009
%C New York, NY
%I Wiley
%M DKFZ-2025-01218
%P e31831
%D 2025
%Z 2025 Sep;72(9):e31831
%X High-risk neuroblastoma is a poor prognosis cancer of the sympathetic nervous system that accounts for a disproportionate number of childhood cancer deaths. Many viable biological targets have been identified, and the number of potential combinations is even larger. Several products have attained marketing authorization for treatment of patients with neuroblastoma. Patient outcomes remain poor, with approximately 50
%K ALK (Other)
%K ATR (Other)
%K B7‐H3 (Other)
%K EZH2 (Other)
%K GD2 (Other)
%K GPC2 (Other)
%K MYCN (Other)
%K clinical trials (Other)
%K drug development (Other)
%K neuroblastoma (Other)
%K relapse (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40509548
%R 10.1002/pbc.31831
%U https://inrepo02.dkfz.de/record/302020